Rodrigo M. Burgos
HIV Residency (PGY3) Director, College of Pharmacy
ID Residency (PGY2) Director, University of Illinois at Chicago
HIV Residency (PGY2) Assistant Director, College of Pharmacy
Contact
Office Phone:
Email:
Related Sites:
About Heading link
Research Interests:
Infectious diseases, virology, HIV, CMV, COVID-19, immunocompromised, opportunistic infections, pharmacoepidemiology
Teaching and Supervision Heading link
PDAT 6: Infectious Diseases (PHAR 506), 1/9/2023 – 4/28/2023
PDAT 6: Infectious Diseases (PHAR 506), 1/9/2023 – 4/28/2023
PDAT 6: Infectious Diseases (PHAR 506), 1/9/2023 – 4/28/2023
PDAT 6: Infectious Diseases (PHAR 506), 1/9/2023 – 4/28/2023
PDAT 6: Infectious Diseases (PHAR 506), 1/9/2023 – 4/28/2023
Spanish for Pharmacists (PMPR 337), 8/22/2022 – 12/2/2022
Spanish for Pharmacists (PMPR 337), 8/22/2022 – 12/2/2022
PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
PDAT 6: Infectious Diseases (PHAR 506), 1/10/2022 – 4/29/2022
Selected Grants
CTA - SGN35-035 - A phase 1, single-blind, dose-escalation study to assess the safety and tolerability of brentuximab vedotin (ADCETRIS�) in subjects with human immunodeficiency virus (HIV), Seagen., 4/6/2022 - 4/7/2030, Obligated Amount: $2420558; Anticipated Amount: $2420558
CTA: A retrospective chart review study of cefiderocol real world outcomes and safety in the treatment of patients with Gram-negative bacterial infections (GNBI) in the US and Europe, Shionogi & Co Ltd., 3/8/2022 - 3/8/2027, Obligated Amount: $26830; Anticipated Amount: $26830
CTA - Observational Cohort Study of Cabenuva Utilization, Outcomes, and Patient Experience in the United States (BEYOND), Research Triangle Inst., 9/30/2021 - 3/29/2022, Obligated Amount: $28904; Anticipated Amount: $28904
COVID19 CTA: CoVPN 3003 A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults..., FHI Development 360 LLC., 8/15/2020 - 8/31/2023, Obligated Amount: $1274900; Anticipated Amount: $1274900
Advanced Manufacturing Technology (AMT) and Cybersecurity Study, Il Manufacturing Excellence Ctr., 2/1/2020 - 12/31/2020, Obligated Amount: $99456; Anticipated Amount: $99456
Merck Investigator Initiated Studies Program, Merck & Co., Inc.., 10/2019 - 12/31/2023, Obligated Amount: $125941.25; No Anticipated Amount Set
Merck Investigator Initiated Studies Program, Merck & Co., Inc.., 10/2019 - 12/31/2023, Obligated Amount: $125941.25; No Anticipated Amount Set
Elbasvir/grazoprevir (Zepatier) for HCV Treatment in Patients with Substance Use, Merck & Co., Inc.., 2019 - Present, No Obligated Amount Set; No Anticipated Amount Set
Merck 1439A-021 Phase III Clinical Trial to Evaluate MK-1439A vs Atripla in Treatment Na�ve Persons Infected with HIV-1, Merck Sharp & Dohme LLC., 9/22/2015 - 6/30/2018, Obligated Amount: $102044; Anticipated Amount: $102044
Selected Publications
Drwiega, Emily N, Danziger, Larry H, Burgos, Rodrigo M, Michienzi, Sarah M. (2023). Commonly Reported Mosquito-Borne Viruses in the United States: A Primer for Pharmacists.. Journal of Pharmacy Practice, 8971900231167929. doi:10.1177/08971900231167929.
Lora, Alfredo J Mena, Burgos, Rodrigo, Borgetti, Scott, Chaisson, Lelia H, Bleasdale, Susan C. (2023). Antimicrobial stewardship and drug formulary restrictions during COVID-19: what is restricted and who decides?. Antimicrobial Stewardship & Healthcare Epidemiology, 3, (1), e116. doi:10.1017/ash.2023.205.
Lora, Alfredo J Mena, Burgos, Rodrigo, Borgetti, Scott, Chaisson, Lelia H, Bleasdale, Susan C. (2023). Remdesivir use and antimicrobial stewardship restrictions during the coronavirus disease 2019 (COVID-19) pandemic in the United States: A cross-sectional survey. Antimicrobial Stewardship & Healthcare Epidemiology, 3, (1), e63. doi:10.1017/ash.2023.146.
Lora, Alfredo J Mena, Herald, Fischer, Lindsey, Brenna, Echeverria, Stephanie, Lira, Sorel, Burgos, Rodrigo M. (2022). 281. Not the sharpest of tools: Procalcitonin and bacterial co-infections in patients admitted with COVID-19. Open Forum Infectious Diseases, 9, (Suppl 2), ofac492.359. doi:10.1093/ofid/ofac492.359.
Mena Lora, Alfredo J, Herald, Fischer, Lindsey, Brenna, Echeverria, Stephanie, Ali, Mirza, Burgos, Rodrigo M. (2022). 930. Weakening the waves: Impact of a syndrome-based antimicrobial stewardship intervention during COVID-19. Open Forum Infectious Diseases, 9, (Supplement_2). doi:10.1093/ofid/ofac492.775.
Mena Lora, Alfredo J, Herald, Fischer, Lindsey, Brenna, Echeverria, Stephanie, Li, Ella, Sanchez, Lawrence, Truesdell, Tiffany, Takhsh, Eden, Lavani, Romeen, Burgos, Rodrigo M. (2022). 1108. Feasibility and Impact of a Monoclonal Antibody Infusion Program in Reaching Vulnerable Underserved Communities. Open Forum Infectious Diseases, 9, (Supplement_2). doi:10.1093/ofid/ofac492.947.
Mena Lora, Alfredo J, Herald, Fischer, Lindsey, Brenna, Burgos, Rodrigo M, Borgetti, Scott, Chaisson, Lelia H, Bleasdale, Susan C. (2022). 929. A Nationwide Survey on the Role of Antimicrobial Stewardship Programs during the COVID-19 Pandemic: What is restricted and who decides?. Open Forum Infectious Diseases, 9, (Supplement_2). doi:10.1093/ofid/ofac492.774.
Mena Lora, Alfredo J, Herald, Fischer, Burgos, Rodrigo M, Borgetti, Scott, Lindsey, Brenna, Chaisson, Lelia H, Bleasdale, Susan C. (2022). 1107. A Survey on Remdesivir Use and Antimicrobial Stewardship Restrictions Throughout the COVID-19 Pandemic. Open Forum Infectious Diseases, 9, (Supplement_2). doi:10.1093/ofid/ofac492.946.
Mena Lora, Alfredo J, Herald, Fischer, Lindsey, Brenna, Borgetti, Scott, Chaisson, Lelia H, Burgos, Rodrigo M, Bleasdale, Susan C. (2022). 1109. Rise and Fall of COVID-19 Therapies Throughout Different Waves of the Pandemic: Results of a Nationwide Survey. Open Forum Infectious Diseases, 9, (Supplement_2). doi:10.1093/ofid/ofac492.948.
Professional Leadership
Panel Member, Section Review Group, NIH-CDC-HIVMA/IDSA, 5/10/2021 - Present
SIDP Taskforce of Diversity, Equity and Inclusion, Society of Infectious Diseases Pharmacists, 1/1/2020 - Present
SIDP Fundraising Committee, 12/20/2019 - Present
Education
Degrees:
Doctor of Pharmacy (Pharm.D.), University of Illinois at Chicago, United States, 2005
Master of Public Health (MPH), University of Illinois at Chicago, United States
Postgraduate Training:
HIV/Infectious Diseases Residency, University of Illinois at Chicago, United States, 2007
Pharmacy Practice Residency, University of Illinois at Chicago, United States, 2006
Chemistry BS Program Completion, University of Illinois at Chicago, United States, 2001
Pre-Pharmacy Program, Truman College, United States, 2000
Chemistry and Pharmacy Program, University of Honduras at Tegucigalpa, Honduras, 1998
Licensures and Certifications
Pharmacist, American Academy of HIV Medicine HIV Pharmacist, 2015 - Present
HIV Expert, American Academy of HIV Medicine HIV Expert, 2008 - Present